Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.

Ruxolitinib cream may help treat severe hair loss in children.

Low-level laser therapy may reduce symptoms and increase hair thickness in lichen planopilaris patients.

Monilethrix is a genetic disorder causing brittle hair, diagnosed using tricoscopy.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Early diagnosis of GLPLS is crucial to prevent complications, but scarring alopecia is irreversible.

The lotion safely and effectively reduces unwanted hair growth.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

A young man had rare serious side effects from an epilepsy drug, leading to stopping the drug.

LC-OCT is an effective new method for diagnosing classic lichen planopilaris.

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Early detection and treatment are crucial to prevent irreversible hair loss in Lichen Planopilaris.

The document concludes that treatment improved skin lesions but not scalp hair loss in two patients with Graham-Little-Piccardi-Lassueur syndrome.

A new botanical treatment improved hair growth and symptoms in lichen planopilaris patients.

A girl with head lice was successfully treated with sulfur ointment and hair shaving.

Pulsed dye laser treatment was effective for a skin condition resistant to other treatments.

A woman's hair loss looked like a different condition due to her hairstyle, and treatment stopped further hair loss but didn't regrow hair.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

A wearable cap-like device using light therapy reduced scalp skin lesions by 71% and was painless.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Upadacitinib effectively treats psoriasis and lichen planus together.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.

The treatment significantly improved lymphocytic cicatricial alopecia symptoms in most patients.

Nilotinib can cause generalized keratosis pilaris.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Low-dose naltrexone helps reduce symptoms and slow down lichen planopilaris without side effects.

Lokivetmab reduced itching in a dog with skin lymphoma.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

Dermoscopy helps diagnose rare GLPLS in males.